Novartis to acquire MorphoSys AG for Euro 2.7 billion to strengthen oncology pipeline
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Collaboration streamlines patient access to oncology clinical trials
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Subscribe To Our Newsletter & Stay Updated